NCT04905511已完成1 期
Preliminary Safety of The TRUE Vascular Graft for Hemodialysis Access (TRUE HD I Study)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Safety, adverse events
研究概览
简要总结
Prospective, nonrandomized, single-arm, single-center, open-label, first-in-human clinical study in subjects with end-stage renal disease (ESRD) and not candidates for an autogenous fistula creation.
详细描述
Prospective, nonrandomized, single-arm, single-center, open-label, first-in-human clinical study in subjects with end-stage renal disease (ESRD) and not candidates for an autogenous fistula creation. Subjects will be followed regularly with office visits at the investigational site at days 15, 29, 57 and weeks 12, 26 for vessel imaging, blood draws and other follow-up tests.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with end stage renal disease (ESRD) who are not, or who are no longer, candidates for creation of a simple autogenous AV fistula (radio-cephalic or brachio-cephalic without requiring transposition) and therefore need placement of an AV graft in the upper extremity to start or maintain hemodialysis therapy.
- •Either on hemodialysis or expected to start hemodialysis within 12 weeks of study conduit implantation.
- •Patients between 18 and 75 years old, inclusive.
- •Life expectancy of at least 1 year.
- •Negative COVID-19 test within 3 days prior to surgery and negative for symptoms within 14 days prior to surgery.
- •Able to communicate meaningfully with investigative staff and able to comply with entire study procedures.
- •Willing and competent to give written informed consent.
排除标准
- •History or evidence of severe cardiac disease (NYHA Functional Class III or IV), myocardial infarction within six months prior to study entry (Day 1), ventricular tachyarrhythmias requiring continuing treatment, or unstable angina.
- •Uncontrolled or poorly controlled diabetes; hospitalization for poor glucose control within the previous 6 months.
- •History or evidence of severe peripheral vascular disease in the upper limbs
- •Known or suspected central vein obstruction on the side of planned graft implantation.
- •Documented hypercoagulable state or history of thromboembolic events or history of repeated venous catheter clotting.
- •Known Positive COVID 19 test result or known exposure to COVID 19 in past 4 months.
- •Known active infection including dental infection, osteomyelitis and other conditions which could present a local or systemic risk of infection.
- •Bleeding diathesis.
- •Contraindication to or known serious allergy to anticoagulant, aspirin, or planned antiplatelet therapy. History of heparin-induced thrombocytopenia.
- •Contraindication to or known serious allergy to penicillin.
- •Ongoing therapy with vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors.
- •Immunodeficiency including AIDS / HIV or active autoimmune disease, or on immunosuppressant therapy.
- •Previous PTFE graft in the operative limb unless the TRUE graft can be placed more proximally than the previous failed graft.
- •More than 1 failed PTFE graft in the operative limb.
结局指标
主要结局
Safety, adverse events
时间窗: 26 weeks
incidence of clinically significant aneurysm, anastomotic bleeding, graft or anastomotic rupture, graft infection, and implant site irritation, inflammation, or infection
Patency
时间窗: 26 weeks
time to loss of patency from implantation by Kaplan Meier
次要结局
- Intervention rate(through 26 weeks)
- Immunology(baseline through 4 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCISpinal Cord Injury, AcuteSpinal Cord Injury at C4 Level With Complete LesionSpinal Cord Injury at C5-C7 Level With Complete LesionNCT04812431S.Biomedics Co., Ltd.5
招募中
1 期
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic LeukemiaB-cell NHLCLLNCT05869279Fondazione Matilde Tettamanti Menotti De Marchi Onlus29
已完成
1 期
Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem CellsLipoatrophyAgingWrinklesNCT01828723Antria6
已完成
1 期
Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal DiseaseEnd-stage Renal DiseaseKidney Failure, ChronicNCT01840956Humacyte, Inc.20
已完成
1 期
Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)Peripheral Artery DiseaseNCT02956993Proteon Therapeutics29